Alert detail

Proposed LCD DL40210: MolDX: Non-Next Generation Sequencing Targeted Molecular Panel Tests for Predictive Testing in Cancer — Palmetto GBA

Policy ID: LCD-DL40210Specialty: OncologyAdded: 6/5/2026lcd
High

What changed

New LCD may alter oncology billing for molecular tests.

Who’s affected: Oncology billing teams

Affected codes

Codes81479

Primary source: View the official CMS/MAC document ↗

Get the action steps and full analysis

This change affects 1 billing code.

Subscribers get the recommended action (“what to do”), the full AI analysis, the LCD revision comparison, and related alerts across your specialty and jurisdiction.

Audit documentation

Building an audit file?

The Tripwire Audit Pack exports 12 months of Oncology policy-change history — every alert with a link to its government source document, as a formatted PDF for compliance distribution plus a machine-readable CSV. Delivered automatically after payment. No account, no call.

Get the Oncology audit pack — $349One-time purchase · not a subscription

Not ready to subscribe?

Get the free weekly reimbursement brief for Oncology— the week’s changes and deadlines, delivered to your inbox. No account required.

Proposed LCD DL40210: MolDX: Non-Next Generation Sequencing Targeted Molecular Panel Tests for Predictive Testing in Cancer — Palmetto GBA